Efficacy of poziotinib in HER2 exon 20 insertion NSCLC patients who received prior platinum-based and HER2 targeted therapies

被引：0
|
作者：
Prelaj, A. [1 ]
Le, X. [2 ]
Proto, C. [3 ]
Baik, C. S. [4 ]
Tchekmedyian, N. [5 ]
Heymach, J. [6 ]
Bhat, G. [7 ]
Cornelissen, R. [8 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Oncol Med Torac Dept, Milan, Italy
[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck, Houston, TX USA
[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[4] Univ Washington, Dept Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[5] City Hope Natl Med Ctr, Med Oncol, Comprehens Canc Ctr, Duarte, CA USA
[6] MD Anderson Canc Ctr, Thorac Oncol, Houston, TX USA
[7] Spectrum Pharmaceut, Dept Clin Sci, Irvine, CA USA
[8] Erasmus MC Univ, Pulm Med, Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2422
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1389P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies
    Le, X.
    Prelaj, A.
    Baik, C.
    Tchekmedyian, N.
    Leu, S.
    Bhat, G.
    Heymach, J. V.
    Cornelissen, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S148
  • [2] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [3] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
    Cornelissen, R.
    Garassino, M. C.
    Le, X.
    Clarke, J.
    Tchekmedyian, N.
    Goldman, J.
    Lebel, F.
    Bhat, G.
    Socinski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S174
  • [5] Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
    Prelaj, Arsela
    Bottiglieri, Achille
    Proto, Claudia
    Lo Russo, Giuseppe
    Signorelli, Diego
    Ferrara, Roberto
    Galli, Giulia
    De Toma, Alessandro
    Viscardi, Giuseppe
    Brambilla, Marta
    Lobefaro, Riccardo
    Nichetti, Federico
    Manglaviti, Sara
    Occhipinti, Mario
    Labianca, Alice
    Ganzinelli, Monica
    Gallucci, Rosaria
    Zilembo, Nicoletta
    Greco, Gabriella Francesca
    Torri, Valter
    de Braud, Filippo
    Garassino, Marina C.
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 235 - 248
  • [6] Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
    Borm, Frank. J.
    Smit, Egbert F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 964 - 966
  • [7] Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance
    Koga, T.
    Kobayashi, Y.
    Tomizawa, K.
    Sesumi, Y.
    Fujino, T.
    Nishino, M.
    Ohara, S.
    Chiba, M.
    Shimoji, M.
    Suda, K.
    Takemoto, T.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S598 - S599
  • [8] Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
    Li, K.
    Bosdet, I.
    Yip, S.
    Ho, C.
    Laskin, J.
    Melosky, B.
    Wang, Y.
    Sun, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1058 - S1059
  • [9] Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
    Le, Xiuning
    Cornelissen, Robin
    Garassino, Marina
    Clarke, Jeffrey M.
    Tchekmedyian, Nishan
    Goldman, Jonathan W.
    Leu, Szu-Yun
    Bhat, Gajanan
    Lebel, Francois
    Heymach, John, V
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 710 - 718
  • [10] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
    Socinski, M. A.
    Cornelissen, R.
    Garassino, M. C.
    Clarke, J.
    Tchekmedyian, N.
    Molina, J.
    Goldman, J. W.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
12345